The complete 5-year outcomes of a study of tildrakizumab for psoriasis show a high rate of sustained disease control combined with a beneficial safety profile throughout more than 5400 patient-years of follow-up. Medscape Medical News
Read More
Tildrakizumab for Psoriasis Shows Resilient Effectiveness Over 5 Years
Byindianadmin
Nov 23, 2020